Want to see IN:SAKAR full AI Analyst Report?
SAKAR Stock Chart & Stats
₹406.55
-₹0.50(-0.17%)
At close: 4:00 PM EST
₹406.55
-₹0.50(-0.17%)
Day’s Range― - ―
52-Week Range₹311.00 - ₹960.00
Previous CloseN/A
Volume6.75K
Average Volume (3M)19.08K
Market Cap
₹19.27B
Enterprise Value₹18.14B
Total Cash (Recent Filing)₹2.60M
Total Debt (Recent Filing)₹553.04M
Price to Earnings (P/E)64.0
Beta0.53
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)13.72
Shares Outstanding21,949,910
10 Day Avg. Volume18,950
30 Day Avg. Volume19,083
Financial Highlights & Ratios
PEG Ratio0.52
Price to Book (P/B)3.42
Price to Sales (P/S)4.41
P/FCF Ratio100.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Accelerating Revenue GrowthSakar scaled top-line growth to 23.4% in FY2026, indicating expanding product adoption and distribution reach. Sustained double-digit revenue growth supports capacity utilization, bargaining power with suppliers, and the ability to invest in manufacturing or commercial expansion over the next several quarters.
Conservative LeverageLeverage fell materially to a conservative ~0.17, improving financial flexibility and lowering refinancing and interest-rate risk. A stronger balance sheet enables durable capital allocation (capex, working capital, or strategic investments) without pressuring earnings in a downturn.
Solid Operating ProfitabilityProfitability in FY2026 shows solid gross and net margins with improved operating performance versus FY2025. Durable positive margins support internal funding for growth, retention of pricing power in core formulations, and a buffer against input-cost swings across a multi-month horizon.
Bears Say
Weak Cash‑flow ConversionAlthough FCF is positive, conversion remains modest—FCF is ~28% of net income after years of negative FCF. Thin cash conversion can constrain sustained reinvestment, dividend capacity or debt reduction, and makes funding growth more sensitive to working-capital swings over months.
Margin VolatilityMaterial swings in gross margins suggest the business is exposed to product-mix, pricing or input-cost pressures that undermine predictability. Persistent margin volatility raises the risk that recent profitability may not be durable without structural cost or portfolio improvements.
Moderate Returns On EquityROE remains in the low double digits at ~9.4%, indicating only moderate capital efficiency. Unless margins or asset turnover materially improve, this level limits longer-term shareholder return potential and may require sustained growth to lift returns meaningfully.
Sakar Healthcare Ltd News
SAKAR FAQ
What was Sakar Healthcare Ltd’s price range in the past 12 months?
Sakar Healthcare Ltd lowest stock price was ₹311.00 and its highest was ₹960.00 in the past 12 months.
What is Sakar Healthcare Ltd’s market cap?
Sakar Healthcare Ltd’s market cap is ₹19.27B.
When is Sakar Healthcare Ltd’s upcoming earnings report date?
Sakar Healthcare Ltd’s upcoming earnings report date is Aug 18, 2026 which is in 29 days.
How were Sakar Healthcare Ltd’s earnings last quarter?
Sakar Healthcare Ltd released its earnings results on May 12, 2026. The company reported ₹4.96 earnings per share for the quarter, beating the consensus estimate of N/A by ₹4.96.
Is Sakar Healthcare Ltd overvalued?
According to Wall Street analysts Sakar Healthcare Ltd’s price is currently Overvalued.
Does Sakar Healthcare Ltd pay dividends?
Sakar Healthcare Ltd does not currently pay dividends.
What is Sakar Healthcare Ltd’s EPS estimate?
Sakar Healthcare Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sakar Healthcare Ltd have?
Sakar Healthcare Ltd has 21,949,910 shares outstanding.
What happened to Sakar Healthcare Ltd’s price movement after its last earnings report?
Sakar Healthcare Ltd reported an EPS of ₹4.96 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 7.562%.
Which hedge fund is a major shareholder of Sakar Healthcare Ltd?
Currently, no hedge funds are holding shares in IN:SAKAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sakar Healthcare Ltd
Sakar Healthcare Limited, founded in 2004 and based in Ahmedabad, India, is a pharmaceutical company actively involved in the full spectrum of drug development, from research and manufacturing to marketing its products. The company's diverse product line includes liquid oral medications, cephalosporin-based drugs (available as tablets, capsules, and dry powder syrups), various injectable forms such as dry powder injections, and liquid injectable solutions (supplied in ampoules, vials, and lyophilized preparations), alongside oral solid dosages. Their comprehensive portfolio addresses approximately 22 distinct therapeutic categories, encompassing treatments for conditions like acidity, malaria, blood clotting, constipation, respiratory issues, pain, infections, depression, allergies, and nutritional deficiencies, among others. Sakar Healthcare also has a significant global reach, distributing its products to roughly 38 countries across regions including Southeast Asia, other parts of Asia, both English and French-speaking African nations, the Middle East and North Africa, and the United States.
Technical Analysis
Ind-Swift Laboratories Ltd.
―
Jagsonpal Pharmaceuticals Ltd.
―
Lincoln Pharmaceuticals Ltd
―
Syncom Formulation (India) Ltd.
―
Venus Remedies Limited
―